E130: Telitacicept for SLE
From The Evidence Based Rheumatology Podcast by Michael Putman
December 22, 2025 · 13 min · Episode 131
About this episode
This episode discusses a significant RCT on the Blys/APRIL inhibitor telitacicept for SLE patients and its potential FDA implications.
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
People in this episode
Host: Michael Putman
Topics covered
- rheumatology
- clinical trials
- SLE
- telitacicept
- FDA
- Blys/APRIL inhibitors
Keywords
- telitacicept
- SLE
- rheumatology
- clinical trial
- FDA
- Blys/APRIL inhibitor
Mentioned in this episode
Organizations: FDA, SLE, SLE-LN
Products: telitacicept
Books & works: NEJM
More episodes of The Evidence Based Rheumatology Podcast
- E135: IL17 and a GLP1? · April 30, 2026 · 11 min
- E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
- E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
- E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
- E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
- E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min
Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.